2-[(3S)-2,5-Dioxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-3-yl]acetic acid

Catalog No. :
ACGCCY749
CAS No. :
1217715-92-8
Molecular Formula :
C11H10N2O4
Molecular Weight :
234.21

IUPAC Name:(S)-2-(2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)acetic acid

2-[(3S)-2,5-Dioxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-3-yl]acetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$114.00Login to see priceInquiryInquiry
100mg95%$159.00Login to see priceInquiryInquiry
250mg95%$220.00Login to see priceInquiryInquiry
1g95%$537.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[(3S)-2,5-Dioxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-3-yl]acetic acid
IUPAC Name(S)-2-(2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)acetic acid
MDL No.MFCD10007533
Molecular FormulaC11H10N2O4
Molecular Weight234.21
SMILESO=C(O)C[C@H](N1)C(NC2=CC=CC=C2C1=O)=O
InChI KeyPZADUWCGARVTQN-QMMMGPOBSA-N
Synonym1H-1,4-Benzodiazepine-3-acetic acid, 2,3,4,5-tetrahydro-2,5-dioxo-, (3S)-;2-[(3s)-2,5-dioxo-2,3,4,5-tetrahydro-1h-1,4-benzodiazepin-3-yl]acetic acid
CAS No.1217715-92-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACGCCY749 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGCCY749 route product structure diagram
    ACGCCY7491217715-92-8
Inquiry

2. ACGCCY749 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGCCY749 route product structure diagram
    ACGCCY7491217715-92-8
Inquiry

Comments (0)